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Abstract
Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents
approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-
2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and
ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the
development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.
Introduction
Melanoma is a process when normal melanocytes undergo
a malignant transformation [1]. Over the past year, there
have been 3 agents approved for treatment of melanoma
by Food and Drug Administration [2-4]. These include
pegylated interferon alpha-2b for stage III melanoma [2],
vemurafenib for unresectable or metastatic melanoma
with BRAF V600E mutation [3], and ipilimumab for treat-
ment of unresectable or metastatic melanoma [4]. The
American Cancer Society estimates that 68,130 new mela-
nomas was diagnosed and approximately 8,700 people
died from melanoma in 2010 [5]. The incidence of Mela-
noma has increased to 22.52 per 100,000 in 2008 from
7.89 per 100,000 in 1975 [6]. Clinical and epidemiological
data suggests increased incidence of melanoma in people
with extensive or repeated exposure to sunlight [7]. Indivi-
duals with family history of melanoma are at significantly
higher risk for developing this malignancy, representing 5-
12% of all reported cases [8]. The risk of melanoma is
associated with high nevi count [9]. One clinically dysplas-
tic nevus is associated with 2 fold risk and 10 or more
have a 12 fold increased risk of developing malignant mel-
anoma [9]. Biopsy of a suspicious lesion is necessary for an
accurate diagnosis and for optimal staging.
Management
Management of Clinically Localized Melanoma
Wide local excision is the treatment of choice for pri-
mary melanoma [10]. The proper resection margin is
based on the thickness of the lesion. According to
NCCN guidelines, melanoma with 1.0 mm or less (T1),
wide excision with a 1.0 cm margin is recommended.
For localized melanomas between 2 and 4 mm thick
(T3), a 2 cm excision is suggested [10]. For thicker mel-
anomas > 4 mm(T4), The U.S. Intergroup Melanoma
Surgical Trial established that a 2-cm margin is ade-
quate. Thick melanomas are associated with a higher
risk of nodal and distant metastases. However, more
extensive resection is unlikely to substantially change
the outcome [1].
Sentinel Lymph node biopsy
Multicenter Selective Lymphadenectomy Trial evaluated
the usefulness of sentinel-node biopsy (SLNB) in the
identification of patients with clinically occult nodal
metastases and to examine the clinical effect of immedi-
ate, complete lymphadenectomy in patients with tumor-
positive sentinel lymph nodes. Among 1269 patients
with intermediate thickness primary melanoma, the
mean estimated 5 year disease free survival was signifi-
cantly higher in the node biopsy group compared to the
observation group at 5 years (78.3% vs. 73.1%; P =
0.009)[11]. Among patients with nodal metastasis, the 5
year survival rate was higher among those who had
immediate lymphadenectomy performed than among
those in whom lymphadenectomy was delayed (72.3%
vs. 52.4%; P = 0.004). Five year melanoma survival rates
were similar between two groups (87.1% vs. 86.6%)[11].
SLNB is currently recommended for melanomas > 1.0
mm thick or greater, 1.0 mm or less with ulceration or * Correspondence: delong_liu@nymc.edu
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resectable solitary in-transit stage III disease.
Adjuvant Systemic Therapy
High Dose Interferon
It is well known that the immune system responds natu-
rally to melanoma and that immune modulation can be
therapeutic for advanced melanoma [1]. The effect of
interferon alfa (IFNa) as a single agent or in combina-
tion has been explored in various clinical trials. A ran-
d o m i z e dc o n t r o ls t u d yb yK i r k w o o de ta lo fI F Na l p h a -
2b administered at 20 MU/m2/d intravenously for 1
month and 10 MU/m2 three times per week subcuta-
neously for 48 weeks was compared to observation
alone, conducted by the Eastern Cooperative Oncology
Group (ECOG) 1684 in 287 patients who had > 4 mm
t h i c km e l a n o m ao rw e r en o d ep o s i t i v e( s t a g eI I b / I I c / I I I )
[12]. A remarkable prolongation of disease free survival
(DFS) (from 1.0 to 1.7 years P = .0023, one-sided) and
prolongation of overall survival (OS) (from 2.8 to 3.8
years P = .0237, one-sided) was noticed with IFN alpha-
2b therapy in this trial. The increase in median DFS and
OS that results from this therapy is correlated with a
42% improvement in the fraction of patients who con-
tinues to be disease-free after treatment with IFN (from
26% to 37%) in comparison to observation [12]. On the
basis of the results of the ECOG 1684 trial, the use of
high-dose IFN2b for the adjuvant therapy of patients
with stage IIB-III melanoma was approved by FDA in
1995 [1].
ECOG 1690 was a prospective, randomized, three-arm
intergroup trial which assessed the efficacy of high-dose
IFN (HDI) alpha-2b (20 MU/m2 IV for 5 d/wk for 4
weeks; 10 MU/m2 SC 3 times/wk for 48 weeks) for 1
year and low-dose IFN (LDI) alpha-2b (3 MU SC 3
times/wk for 2 years) for 2 years versus observations
(Obs) in high-risk (stage IIB and III) melanoma. The
estimated 5 year RFS rates for the HDI, LDI, and Obs
arms were 44%, 40%, and 35%, respectively [13]. Hence
RFS benefit of IFN alpha2b is dose-dependent and sig-
nificant for HDI. However, unlike ECOG 1684, the
ECOG 1690 failed to show any difference in OS
between different arms [13].
Additional pooled analysis of E1684, E1694, and
E18952 confirmed an improvement in RFS in patients
with high risk resected melanoma (P = .006) but failed
to demonstrate a significant improvement in overall sur-
vival. There are ongoing studies regarding modified dos-
ing regimens, defining mechanism of action, and finding
more effective combination regimens incorporating
vaccines.
Pegylated Interferon
European Organization for Research and Treatment of
Cancer (EORTC) 18991 organized a study on stage III
melanoma patients, evaluating the efficacy and toxicity
of long term pegylated interferon (PEG-IFN) vs. Obser-
vation. PEG-IFN (Induction at 6 μg/Kg/wk, sc, 8 weeks;
followed by maintenance at 3 μg/Kg/wk, sc) therapy for
5 years was compared to Obs. in 1256 patients with
stage III melanoma (any T, N1-2, M0 without in-transit
metastases). Four-year relapse-free survival was signifi-
cantly better in the interferon group in comparison to
the observation group (45.6% vs. 38.9%). However, there
was no significant effect of pegylated interferon on OS
[2].
Based on this data from EORTC 18991, pegylated
interferon received approval by the FDA in 2011 as
adjuvant therapy for melanoma with nodal involvement,
demonstrating a sustained impact on RFS in patients
with lymph node positive melanoma. Weekly dose of
pegylated interferon appears more convenient than 3
times weekly injection of high dose interferon [2].
When treating patients with adjuvant high-dose inter-
feron or pegylated interferon, it should be based on
individualization of each patient factoring in past medi-
cal history, performance status, and co-morbidities.
According to NCCN guidelines, adjuvant treatment
options for stage IIB or IIC melanoma (2.0-4.0 mm with
ulceration or > 4.0 mm) include clinical trials, observa-
tion, or high-dose interferon. For stage III disease (posi-
tive nodes), options include clinical trials, observation or
interferon alfa. In addition to interferon alfa, pegylated
interferon is an option in completely resected stage III
melanoma. Currently, high-dose interferon and pegy-
lated interferon is category 2B due to its limited benefits
compared to risks of possible side effects.
Adjuvant Radiation Treatment
Early stage melanoma is often cured with primary sur-
gery. However, there are situations in which adjuvant
radiation therapy (RT) should be considered. According
to NCCN guidelines, the following situations should be
considered for adjuvant RT: those with inadequate mar-
gins, high risk nodal disease such as multiple positive
nodes, larger nodes, those with macrovascular extranod-
ular soft tissue extension, melanoma involving cervical
lymph nodes, and desmoplastic neurotropic melanoma
which tends to be more aggressive.
Treatment of Unresectable Metastatic (Stage IV) Melanoma
The incidence of metastatic melanoma has increased
over the past three decades, and the death rate con-
tinues to rise faster than the rate with most cancers
[14]. The survival rate for patients with metastatic mela-
noma is low, with an expected 2-year survival rate of 10
to 20%. In the United States alone, an estimated 8700
persons died from melanoma in 2010 [5].
Surgery
A small group of patients may potentially benefit from
surgery for distant metastatic (stage IV) melanoma. The
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potentially curative in selected few cases [1]. Situations
in which the benefit of surgery is definitive include: ane-
mia secondary to occult bleeding from intestinal metas-
tasis, small bowel metastasis resulting in bowel
obstruction, cutaneous or subcutaneous ulceration due
to metastasis, neurologic symptoms as a result of lymph
node metastasis, symptomatic brain metastasis, and life-
threatening hemorrhage due to metastasis. There is no
standard adjuvant therapy post resection of metastatic
melanoma [1].
Chemotherapy
In 1975, dacarbazine (DTIC) became the first che-
motherapeutic agent approved by FDA for the treatment
of metastatic melanoma. The response rates with dacar-
bazine were 15-25%, with median response durations of
5-6 months, but less than 5% of complete responses
[15]. Temozolomide and fotemustine have also been
compared with DTIC [16,17]. A number of regimens
combining dacarbazine with other cytotoxic agents,
tamoxifen, or interferon alfa have shown promising
response rates in single-institution phase 2 trials and
potential survival advantages in phase 3 trials. However,
despite extensive investigation, no randomized con-
trolled trials have proven these approaches to be super-
ior to dacarbazine alone [15].
Immunotherapy for Systemic Treatment of Stage IV
Melanoma
Immunotherapy for melanoma and other cancer types
have been widely studied [18]. Interleukin-2, monoclonal
antibodies, and cellular therapy have been in active clini-
cal and preclinical trials.
High-dose Interleukin-2
The intravenous administration of high-dose interleu-
kin-2 (IL-2) constitutes an effective treatment for
patients with metastatic melanoma and the treatment
capable of providing long-term complete responses and
potential cure in these patients [1]. IL-2 alone, is ineffec-
tive on cancer cells directly, and its antitumor activity is
dependent on its ability to modulate immunologic
responses in the host [19]. In the initial study of high-
dose IL-2 by Atkins et al, the overall response rate was
16% (95% CI, 12% to 21%), median duration of response
for all responders was 8.9 months, fifty-eight percent of
the responders remained progression-free at 12 months,
the median survival duration for all patients in the study
was 11.4 months, and there were no relapses in
responding patients after 30 months [19]. The unique-
ness of IL-2 therapy is its capability to mediate durable
complete responses in patients with widespread meta-
static disease. With a median follow-up of 62 months,
47% of the responding patients were still alive [19].
Although chemotherapy regimens and high-dose IL-2
show similar regression rates, only high-dose IL-2 is
capable of achieving the level of durable complete
responses [1]. High-dose IL-2 was approved by the FDA
for the treatment of metastatic melanoma in January
1998 due to its ability to mediate durable responses.
Most of the severe toxicities resembled the clinical man-
ifestations of septic shock such as hypotension, supra-
ventricular tachycardia, and respiratory distress
syndrome. Nausea, vomiting, and diarrhea were com-
mon, but life-threatening gastrointestinal side effects
were rare. Mental status changes were also common
and could be severe. Although elevations of creatinine
levels were common, all patients were able to recover
renal function after completion of therapy. Infections
were reported in 15% of patients, with life-threatening
infections or sepsis occurring in 3%[19].
Novel Agents for Targeted Therapy
Ipilimumab
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
is an immunomodulatory molecule, expressed on both
CD8+ and CD4+ T cells, allowing peripheral tolerance
by suppressing T-cell activation and proliferation (Figure
1)[1]. Activation through CTLA-4 results in a reduction
in T-cell responsiveness and increases the threshold for
T-cell activation [1]. Blockade of CTLA-4 function
results in enhancement of antitumor immunity, since
tumors primarily express non-mutated, self-antigens.
Closer look on these findings in clinical trials revealed
that the utilization of an anti-CTLA-4 blocking antibody
mediated objective responses in approximately 15% of
patients with metastatic melanoma [20].
Ipilimumab, a fully humanized IgG1 monoclonal anti-
body, blocks CTLA-4, thus amplifying T-cell activation
and proliferation [21]. Ipilimumab has shown activity in
patients with metastatic melanoma when it was used as
monotherapy in phase 2 study [22].
A dose-dependent response was seen in group receiv-
ing ipilimumab at a dose of 10 mg per kilogram in a
phase 2 study [22]. In the randomized phase 2 study by
Hersh et al combination of DTIC and Ipilimumab was
associated with durable objective responses without new
adverse events [23].
Ipilimumab has also demonstrated activity when com-
bined with other agents, including cancer vaccines [20].
One well-studied cancer vaccine consists of Human
Leukocyte Antigen (HLA) A-201 restricted peptides
derived from the melanoma protein, glycoprotein 100
(gp100). Monotherapy with gp100 generates immune
r e s p o n s e sb u th a sl i m i t e da n titumor activity [24]. With
no proven standard of care, Hodi et al. used gp100 as
an active control for phase 3 study, which evaluated
whether ipilimumab with or without gp100 improves
overall survival, as compared with gp100 alone, among
Lee et al. Journal of Hematology & Oncology 2012, 5:3
http://www.jhoonline.org/content/5/1/3
Page 3 of 7patients with metastatic melanoma [4]. The median
overall survival in the ipilimumab-plus-gp100 group was
10.0 months vs. 10.1 months in the ipilimumab-alone
group and median overall survival is 6.4 months in the
gp100-alone. OS rates in the ipilimumab-plus-gp100
group, the ipilimumab-alone group, and the gp100-alone
group, respectively, were 43.6%, 45.6%, and 25.3% at 12
m o n t h s ,3 0 . 0 % ,3 3 . 2 % ,a n d1 6 . 3 %a t1 8m o n t h s ,a n d
21.6%, 23.5%, and 13.7% at 24 months [4]. According to
Hodi et al., the effect of ipilimumab on overall survival
was independent of age, sex, baseline serum lactate
dehydrogenase levels, metastasis stage of disease, and
previous exposure interleukin-2 therapy [4].
Dacarbazine has been the drug most frequently com-
pared with new agents or combination therapies in ran-
domized trials involving patients with melanoma,
although it has never been shown to improve survival in
randomized, controlled studies [25]. Phase 3 study was
conducted by Wolchok et al. to determine whether ipili-
mumab (at a dose of 10 mg per kilogram) plus dacarba-
zine, as compared with dacarbazine and placebo
improves overall survival inp a t i e n t sw i t hp r e v i o u s l y
untreated metastatic melanoma [26]. The median overall
survival in the ipilimumab-dacarbazine group was 11.2
month and 9.1 months in the dacarbazine group, with
estimated survival rates in the two groups, respectively,
of 47.3% and 36.3% at 1 year, 28.5% and 17.9% at 2
years, and 20.8% and 12.2% at 3 years. There was a 24%
decrease in the risk of progression in the ipilimumab-
dacarbazine group as compared with the dacarbazine
group (hazard ratio for progression, 0.76; P = 0.006)[26].
However, there was a higher incidence in the ipilimu-
mab-dacarbazine group than in the dacarbazine group
included elevation of alanine aminotransferase levels (in
33.2% of patients vs. 5.6%), elevation of aspartate amino-
transferase levels (29.1% vs. 5.6%), diarrhea (36.4% vs.
24.7%), pruritus (29.6% vs. 8.8%), and rash (24.7% vs.
6.8%)[26]. Grade 3 or 4 adverse events occurred in
56.3% of patients receiving ipilimumab plus dacarbazine
and in comparison 27.5% of patients receiving placebo
plus dacarbazine (P < 0.001). The most common grade
3 or 4 immune-mediated adverse reaction was immune-
mediated hepatitis, which was observed in 78 patients in
the ipilimumab-dacarbazine group (31.6%) and in 6
patients in the dacarbazine group (2.4%). Grade 3 or 4
immune-mediated enterocolitis was detected in 12
patients in the ipilimumab-dacarbazine group (4.9%)
and no patients in the dacarbazine group [26]. The
hepatic complications were generally reversible. Patients
who received glucocorticoids or other immunosuppres-
sant agents after the emergence of high-grade immune-
mediated hepatitis were 80.8% in the ipilimumab-dacar-
bazine group and 33.3% in the dacarbazine group. No
p a t i e n td i e df r o mt h ec o mplications of immune-
mediated hepatitis or enterocolitis during the course of
the study [26]. Based on phase 3 studies by Hodi et al,
and Wolchok et al, ipilimumab was approved by FDA in
2011 for treatment of unresectable or metastatic
Figure 1 The mechanism of action of anti-CTLA-4 monoclonal antibody.
Lee et al. Journal of Hematology & Oncology 2012, 5:3
http://www.jhoonline.org/content/5/1/3
Page 4 of 7melanoma at a dose of 10 mg per kilogram every 3
weeks for 4 doses.
Adoptive T-Cell Therapy
Adoptive T cell therapy (ATCT) consists of isolating
tumor reactive lymphocytes from a cancer patient,
growing and activating them in vitro, and infusing them
back into same patient. ATCT was first described in
1988. Rosenberg et al used autologous tumor-infiltrating
lymphocytes (TIL) derived from freshly resected meta-
static melanomas.
Morgan et al did the first clinical trial that demon-
strated anti-tumor responses by adoptive cell transfer of
lymphocytes transduced with retroviral encoding T-cell
receptors (TCR). The first clinical trial to successfully
mediate the regression of human cancer by ATCT used
genetically engineered autologous lymphocytes [27]. Six-
teen patients were treated in the trial. These patients
had lymphocytes with a TCR reactive with the mela-
noma-associated antigen recognized by T cells
(MART1), which was isolated from highly reactive TIL.
Two patients underwent regression of liver and lung
hilum metastases respectively and both remained disease
free 2 years later. TCRs with far greater affinity for the
MART1 melanoma antigen have been identified and are
now being evaluated in clinical gene therapy trials [28].
Phage display techniques have been used to generate
TCRs with 106 times the affinity of a natural TCR direc-
ted against the cancer- testis antigen NY-ESO-1 (present
on common epithelial cancers and 10-50% of melano-
mas). Robbins et al recently conducted a clinical trial
targeting the NY-ESO-1 antigen with TILs. The study
showed objective responses in 6 out of 11 patients, of
which 2 patients had complete response [28]. These stu-
dies suggest ATCT can be a potent and effective therapy
for malignant melanoma. A major problem is that it is
highly personalized and labor-intensive which makes its
commercial use difficult.
Vemurafenib
A search for mutations in the mitogen-activated protein
(MAP) kinase pathway in various common cancers by
Davies et al, revealed that 40% to 60% of melanomas,
and a 7 to 8% of all cancers carry an activating mutation
in the gene encoding the serine-threonine protein kinase
BRAF (Figure 2)[29,30]. Although other activating muta-
tions are known (e.g., BRAF V600K and BRAF V600R),
approximately 90% of these mutations result in the sub-
stitution of glutamic acid for valine at codon 600 (BRAF
V600E)[5]. This BRAF mutation makes it constitutively
activated and leads to constitutive activation of the
MAP kinase pathway [31].
Vemurafenib is a potent and specific inhibitor of
BRAF with the V600E mutation. It has marked
antitumor effects against melanoma cell lines with the
BRAF V600E mutation only. It is inactive in the cell
lines with wild type BRAF [32].
Flaherty et al. conducted a Phase I and II trials for
vemurafenib study in patients with unresectable, pre-
v i o u s l yu n t r e a t e ds t a g eI I I Co rs t a g eI Vm e l a n o m at h a t
tested positive for the BRAF V600E mutation [31]. A
phase 1 trial established the maximum tolerated dose to
be 960 mg twice daily which showed responses against
the tumor [31]. A phase 2 trial involving patients who
had received previous treatment for melanoma with the
BRAF V600E mutation displayed a confirmed response
rate of 53%, with a median duration of response of 6.7
months. The levels of phosphorylated extracellular sig-
nal-regulated kinase (ERK), cyclin D1, and Ki-67 were
markedly reduced at day 15 as compared with baseline
in all specimens examined. This study proposed that
vemurafenib inhibited the MAP kinase pathway, result-
ing in decreased cyclin D1 levels and decreased prolif-
eration. A marked decrease in tumor uptake of FDG
was noted at day 15 in virtually all patients [31].
Subsequently, Phase III trial was conducted in 680
patients with previously untreated, unresectable stage
IIIC or stage IV melanoma with BRAF V600E muta-
tions. The patients were randomized to vemurafenib
(960 mg po bid) or dacarbazine (1,000 mg/m
2,I V ,q 3 w )
[33]. Patients were evaluated for tumor responses after
weeks 6, 12, and then q9 weeks [34]. There was an
increase in median survival from 8 months for dacarba-
zine to 12.3 months for vemurafenib [3]. Crossover of
patients in the dacarbazine group was allowed subse-
quently to vemurafenib group, and the protocol was
amended accordingly. Median follow-up for the interim
analysis was 3.8 months for patients in the vemurafenib
group and 2.3 months for those in the dacarbazine
group [3]. A total of 672 patients were evaluated for OS.
At 6 months, OS was 84% in the vemurafenib group
compared to 64% in the dacarbazine group [3]. Esti-
mated median progression-free survival (PFS) in the
vemurafenib group and in the dacarbazine group was
5.3 months and 1.6 months respectively [3].
The most common adverse events in the vemurafenib
group were cutaneous events, arthralgias, and fatigue;
photosensitivity skin reactions of grade 2 or 3 were seen
in 12% of the patients. Among patients treated with
vemurafenib, 18% were reported to have at least one
squamous-cell carcinoma of the skin or keratoa-
canthoma [3]. Median time to the appearance of a cuta-
neous squamous-cell carcinoma was 8 weeks; most of
the carcinomas were resected, and in no case did they
lead to treatment discontinuation. These squamous-cell
carcinoma and keratoacanthoma type are well-differen-
tiated tumors with very low invasive potential and vir-
tually no metastatic capabilities [31]. The mechanism of
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vemurafenib administration is unclear, but it is hypothe-
sized to involve the activating effect of vemurafenib on
pre-neoplastic cells in which wild-type BRAF is further
primed by upstream pathway activation [3].
Vemurafenib displayed a relative reduction of 63% in
the risk of death and of 74% in the risk of tumor pro-
gression in untreated, unresectable stage IIIC or stage
IV melanoma with the BRAF V600E mutation, in com-
parison with treatment with dacarbazine [3]. Vemurafe-
nib 960 mg, orally administered twice daily was
approved by FDA in 2011 to treat patients with meta-
static or unresectable melanoma.
KIT Mutation
Melanomas present on mucosal membranes, acral skin
(soles, palms, and nail bed), and on chronic sun-induced
damage areas often do not have mutations within the
genes of MAP kinase pathway such as BRAF and NRAS,
which are commonly mutated in intermittent sun-
exposed areas. This raises the question of other aberra-
tions in MAP kinase system. Curtin et al studied 102
patients with primary melanoma for DNA copy number
aberrations specific to melanoma subtypes where muta-
tions in BRAF and NRAS are infrequent. He found a
narrow amplification on 4q12 and analyzed candidate
genes within. Mutations and/or copy number of KIT
were increased in 39% of mucosal, 36% of acral, and
28% of melanomas on chronically sun-damaged skin,
but 0% on melanomas of non-chronic sun exposed skin
[35].
KIT mutations are frequently found in gastrointestinal
stromal tumors (GIST) and have been shown to be
highly sensitive to imatinib, a tyrosine kinase inhibitor
(TKI) targeting ABL, PDGF-R, and KIT, thus providing
a potential for targeted therapy in patients with KIT
mutations in melanoma. Two new TKI agents have also
been approved [36]. The initial Phase II trials using ima-
tinib showed no objective benefit and poor survival rate
in patients with metastatic melanoma [37].
More recently Carvajal et al conducted an open-label,
phase 2 trial, with advanced unresectable melanoma
with KIT alterations and amplifications. From this trial,
28 patients were administered with imatinib at a dose of
400 mg, twice daily. Two complete responses lasting 94
weeks and ongoing, 2 durable partial responses lasting
53 and 89 (ongoing) weeks, and 2 transient partial
responses lasting 12 and 18 weeks among the 25 evalu-
able patients were observed. The overall durable
response rate was 16%, with a median time to progres-
sion of 12 weeks, and a median overall survival of 46.3
weeks [38]. There is a similar phase II study conducted
in China by Guo et al. In this phase II trial, 43 patients
with metastatic melanoma harboring c-KIT mutations
were treated with imatinib at 400 mg daily until disease
progression or intolerable toxicities with a median fol-
low up of 12 months. It showed 10 patients (23.3%) dis-
played partial response and 13 patients (30.2%) had
stable disease with 18 of 43 patients (41.9%) showing
regression of tumor mass. Based on these data, imatinib
has shown promising results as a therapeutic agent in
metastatic melanoma patients with c-KIT mutations
[30].
Conclusion and future directions
Pegylated interferon alpha-2b, vemurafenib and ipilimu-
mab were approved for treatment of melanoma by Food
and Drug Administration in the past year. Novel agents,
including tyrosine kinase inhibitors and adoptive cellular
therapy, are being explored. It is foreseeable that agents
with novel mechanisms of action will be studied for this
challenging malignancy [39-41].
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